Literature DB >> 11160004

Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

M L Bernardini1, J Arondel, I Martini, A Aidara, P J Sansonetti.   

Abstract

Because the use of live attenuated mutants of Shigella spp. represents a promising approach to protection against bacillary dysentery (M. E. Etherridge, A. T. M. Shamsul Hoque, and D. A. Sack, Lab. Anim. Sci. 46:61-66, 1996), it becomes essential to rationalize this approach in animal models in order to optimize attenuation of virulence in the vaccine candidates, as well as their route and mode of administration, and to define the correlates of protection. In this study, we have compared three strains of Shigella flexneri 5--the wild-type M90T, an aroC mutant, and a double purE aroC mutant--for their pathogenicity, immunogenicity, and protective capacity. Protection against keratoconjunctivitis, induced by wild-type M90T, was used as the protection read out in guinea pigs that were inoculated either intranasally or intragastrically. Following intranasal immunization, the aroC mutant elicited weak nasal tissue destruction compared to M90T and achieved protection correlated with high levels of local anti-lipopolysaccharide immunoglobulin A (IgA), whereas the purE aroC double mutant, which also elicited weak tissue destruction, was not protective and elicited a low IgA response. Conversely, following intragastric immunization, only the M90T purE aroC double mutant elicited protection compared to both the aroC mutant and the wild-type strain. This mutant caused mild inflammatory destruction, particularly at the level of Peyer's patches, but it persisted much longer within the tissues. This could represent an essential parameter of the protective response that, in this case, did not clearly correlate with high anti-lipopolysaccharide IgA titers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160004      PMCID: PMC97988          DOI: 10.1128/IAI.69.2.1072-1083.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  57 in total

1.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

2.  Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors:  D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

3.  Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes.

Authors:  N K Verma; A A Lindberg
Journal:  Vaccine       Date:  1991-01       Impact factor: 3.641

4.  Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants.

Authors:  A Cersini; A M Salvia; M L Bernardini
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  A systemic downregulation of gamma interferon production is associated with acute shigellosis.

Authors:  R Raqib; A Gustafsson; J Andersson; M Bakhiet
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin.

Authors:  M L Bernardini; J Mounier; H d'Hauteville; M Coquis-Rondon; P J Sansonetti
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.

Authors:  K L Kotloff; J P Winickoff; B Ivanoff; J D Clemens; D L Swerdlow; P J Sansonetti; G K Adak; M M Levine
Journal:  Bull World Health Organ       Date:  1999       Impact factor: 9.408

8.  Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.

Authors:  A B Hartman; M M Venkatesan
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

10.  Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease.

Authors:  D Islam; P K Bardhan; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more
  2 in total

1.  Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants.

Authors:  Antonella Cersini; Maria Celeste Martino; Irene Martini; Giacomo Rossi; Maria Lina Bernardini
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

2.  Hypoxic stress, hepatocytes and CACO-2 viability and susceptibility to Shigella flexneri invasion.

Authors:  Camila Bárbara Cantalupo Lima; Sânia Alves Dos Santos; Dahir Ramos de Andrade Júnior
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2013 Sep-Oct       Impact factor: 1.846

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.